Back to Citadel Advisors LLC Citadel Advisors LLC

DSGN

22 quarters

Position history for Citadel Advisors LLCCitadel Advisors LLC's holdings in Design Therapeutics, Inc.

Yes. Citadel Advisors holds 81,971 shares of DSGN (Design Therapeutics), worth $1.2M, as of its Q2 2026 13F filing. It reduced the position by 149,542 shares (-64.6%) from Q1 2026. Citadel Advisors has held DSGN in every 13F on record since Q1 2021, 22 quarterly filings.

Current Value

$1.2M

Current Shares

81,971

Total Value Change

-$74.6M

Total Shares Change

-2.5M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
81,971
-64.6%
$1.2M0.0%$14.47
0
2026-Q1
Decreased
231,513
-49.7%
$2.5M0.0%$10.00
0
2025-Q4
Decreased
459,874
-17.0%
$4.3M0.0%$9.79
0
2025-Q3
Decreased
554,020
-34.1%
$4.2M0.0%$6.85
0
2025-Q2
Decreased
840,793
-12.7%
$2.8M0.0%$3.57
0
2025-Q1
Increased
963,460
+0.5%
$3.7M0.0%$4.21
27
2024-Q4
Increased
958,793
+66.6%
$5.9M0.0%$6.17
40
2024-Q3
Increased
575,550
+88.9%
$3.1M0.0%$5.33
41
2024-Q2
Decreased
304,630
-65.2%
$1M0.0%$3.35
0
2024-Q1
Decreased
874,777
-52.3%
$3.5M0.0%$4.03
0
2023-Q4
Decreased
1.8M
-32.1%
$4.9M0.0%$2.65
0
2023-Q3
Decreased
2.7M
-5.5%
$6.4M0.0%$2.36
0
2023-Q2
Decreased
2.9M
-0.3%
$18M0.0%$5.82
0
2023-Q1
Increased
2.9M
+14.5%
$16.5M0.0%$5.70
32
2022-Q4
Increased
2.5M
+3.3%
$25.7M0.0%$10.26
30
2022-Q3
Decreased
2.4M
-4.9%
$40.5M0.0%$16.79
0
2022-Q2
Increased
2.5M
+0.4%
$35.6M0.0%$14.02
29
2022-Q1
Unchanged
2.5M
0.0%
$40.9M0.0%$16.01
0
2021-Q4
Decreased
2.5M
-1.5%
$54.3M0.0%$21.29
0
2021-Q3
Increased
2.6M
+0.3%
$37.8M0.0%$13.99
29
2021-Q2
Increased
2.6M
+1.2%
$49.9M0.0%$21.71
30
2021-Q1
New
2.5M
-
$75.8M0.0%$29.52
41

Other major holders of DSGN: RA Capital Management, L.P., Point72 Asset Management, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used